Minimal Residual Disease Detected by the 7NB-mRNAs ddPCR Assay Is Associated with Disease Progression in High-Risk Neuroblastoma Patients: A Prospective Multicenter Observational Study in Japan

1.

2.

3.

4.

Delloye-Bourgeois, C.; Castellani, V. Hijacking of Embryonic Programs by Neural Crest-Derived Neuroblastoma: From Physiological Migration to Metastatic Dissemination. Front. Mol. Neurosci. 2019, 12, 52. [CrossRef]

Ponzoni, M.; Bachetti, T.; Corrias, M.V.; Brignole, C.; Pastorino, F.; Calarco, E.; Bensa, V.; Giusto, E.; Ceccherini, I.; Perri, P. Recent

advances in the developmental origin of neuroblastoma: An overview. J. Exp. Clin. Cancer Res. 2022, 41, 92. [CrossRef]

Brodeur, G.M. Neuroblastoma: Biological insights into a clinical enigma. Nat. Rev. Cancer 2003, 3, 203–216. [CrossRef] [PubMed]

Maris, J.M.; Hogarty, M.D.; Bagatell, R.; Cohn, S.L. Neuroblastoma. Lancet 2007, 369, 2106–2120. [CrossRef] [PubMed]

Biology 2023, 12, 1350

5.

6.

7.

8.

9.

10.

11.

12.

13.

14.

15.

16.

17.

18.

19.

20.

21.

22.

23.

24.

25.

10 of 10

Monclair, T.; Brodeur, G.M.; Ambros, P.F.; Brisse, H.J.; Cecchetto, G.; Holmes, K.; Kaneko, M.; London, W.B.; Matthay, K.K.;

Nuchtern, J.G.; et al. The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report. J. Clin.

Oncol. 2009, 27, 298–303. [CrossRef] [PubMed]

Cohn, S.L.; Pearson, A.D.J.; London, W.B.; Monclair, T.; Ambros, P.F.; Brodeur, G.M.; Faldum, A.; Hero, B.; Iehara, T.; Machin, D.;

et al. The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report. J. Clin. Oncol.

2009, 27, 289–297. [CrossRef]

Liang, W.H.; Federico, S.M.; London, W.B.; Naranjo, A.; Irwin, M.S.; Volchenboum, S.L.; Cohn, S.L. Tailoring Therapy for Children

With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future. JCO Clin. Cancer Inform. 2020, 4, 895–905.

[CrossRef]

Park, J.R.; Bagatell, R.; London, W.B.; Maris, J.M.; Cohn, S.L.; Mattay, K.K.; Hogarty, M.; Committee COGN. Children’s Oncology

Group’s 2013 blueprint for research: Neuroblastoma. Pediatr. Blood Cancer 2013, 60, 985–993. [CrossRef]

Tolbert, V.P.; Matthay, K.K. Neuroblastoma: Clinical and biological approach to risk stratification and treatment. Cell Tissue Res.

2018, 372, 195–209. [CrossRef]

Beiske, K.; Ambros, P.F.; Burchill, S.A.; Cheung, I.Y.; Swerts, K. Detecting minimal residual disease in neuroblastoma patients-the

present state of the art. Cancer Lett. 2005, 228, 229–240. [CrossRef]

Brownhill, S.C.; Burchill, S.A. PCR-based amplification of circulating RNAs as prognostic and predictive biomarkers—Focus on

neuroblastoma. Pract. Lab. Med. 2017, 7, 41–44. [CrossRef] [PubMed]

Stutterheim, J.; Zappeij-Kannegieter, L.; Versteeg, R.; Caron, H.N.; van der Schoot, C.E.; Tytgat, G.A. The prognostic value of fast

molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma. Eur. J. Cancer 2011, 47, 1193–1202.

[CrossRef]

Viprey, V.F.; Gregory, W.M.; Corrias, M.V.; Tchirkov, A.; Swerts, K.; Vicha, A.; Dallorso, S.; Brock, P.; Luksch, R.; Valteau-Couanet,

D.; et al. Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: A European HR-NBL1/SIOPEN study.

J. Clin. Oncol. 2014, 32, 1074–1083. [CrossRef] [PubMed]

Cheung, N.K.; Ostrovnaya, I.; Kuk, D.; Cheung, I.Y. Bone marrow minimal residual disease was an early response marker and a

consistent independent predictor of survival after anti-GD2 immunotherapy. J. Clin. Oncol. 2015, 33, 755–763. [CrossRef]

Yanez, Y.; Hervas, D.; Grau, E.; Oltra, S.; Perez, G.; Palanca, S.; Bermudez, M.; Marquez, C.; Canete, A.; Castel, V. TH and DCX

mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients. J. Cancer Res. Clin. Oncol.

2016, 142, 573–580. [CrossRef]

Marachelian, A.; Villablanca, J.G.; Liu, C.W.; Liu, B.; Goodarzian, F.; Lai, H.A.; Shimada, H.; Tran, H.C.; Parra, J.A.; Gallego, R.;

et al. Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma

Provides a New Biomarker for Disease and Prognosis. Clin. Cancer Res. 2017, 23, 5374–5383. [CrossRef]

Thwin, K.K.M.; Ishida, T.; Uemura, S.; Yamamoto, N.; Lin, K.S.; Tamura, A.; Kozaki, A.; Saito, A.; Kishimoto, K.; Mori, T.; et al.

Level of Seven Neuroblastoma-Associated mRNAs Detected by Droplet Digital PCR Is Associated with Tumor Relapse/Regrowth

of High-Risk Neuroblastoma Patients. J. Mol. Diagn. 2020, 22, 236–246. [CrossRef]

Bustin, S.A.; Benes, V.; Garson, J.A.; Hellemans, J.; Huggett, J.; Kubista, M.; Mueller, R.; Nolan, T.; Pfaffl, M.W.; Shipley, G.L.; et al.

The MIQE guidelines: Minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 2009, 55,

611–622. [CrossRef]

Huggett, J.F.; Foy, C.A.; Benes, V.; Emslie, K.; Garson, J.A.; Haynes, R.; Hellemans, J.; Kubista, M.; Mueller, R.D.; Nolan, T.; et al.

The digital MIQE guidelines: Minimum information for publication of quantitative digital PCR experiments. Clin. Chem. 2013, 59,

892–902. [CrossRef] [PubMed]

Burchill, S.A.; Beiske, K.; Shimada, H.; Ambros, P.F.; Seeger, R.; Tytgat, G.A.; Brock, P.R.; Haber, M.; Park, J.R.; Berthold, F.

Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on

behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group. Cancer 2017, 123, 1095–1105. [CrossRef]

Brodeur, G.M.; Pritchard, J.; Berthold, F.; Carlsen, N.L.; Castel, V.; Castelberry, R.P.; De Bernardi, B.; Evans, A.E.; Favrot, M.;

Hedborg, F.; et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J. Clin.

Oncol. 1993, 11, 1466–1477. [CrossRef] [PubMed]

Kanda, Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013, 48,

452–458. [CrossRef] [PubMed]

Hishiki, T.; Matsumoto, K.; Ohira, M.; Kamijo, T.; Shichino, H.; Kuroda, T.; Yoneda, A.; Soejima, T.; Nakazawa, A.; Takimoto, T.;

et al. Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: A report from the Japan Childhood

Cancer Group Neuroblastoma Committee (JNBSG). Int. J. Clin. Oncol. 2018, 23, 965–973. [CrossRef] [PubMed]

Moss, T.J.; Sanders, D.G. Detection of neuroblastoma cells in blood. J. Clin. Oncol. 1990, 8, 736–740. [CrossRef]

Seeger, R.C.; Reynolds, C.P.; Gallego, R.; Stram, D.O.; Gerbing, R.B.; Matthay, K.K. Quantitative tumor cell content of bone

marrow and blood as a predictor of outcome in stage IV neuroblastoma: A Children’s Cancer Group Study. J. Clin. Oncol. 2000,

18, 4067–4076. [CrossRef]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual

author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to

people or property resulting from any ideas, methods, instructions or products referred to in the content.

...